コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nfection), and 15-60 days of a positive PCR (convalescence).
2 markers occur during the first 12 months of convalescence.
3 and if secondary transmission occurs during convalescence.
4 amples obtained during the acute illness and convalescence.
5 tients who provided multiple samples through convalescence.
6 virus (EBV) during both acute infection and convalescence.
7 le, and similar patterns of clearance during convalescence.
8 ut the entire course of COVID-19 disease and convalescence.
9 ined cytotoxic transcriptional programs into convalescence.
10 t not heterologous, isolates were boosted in convalescence.
11 ular impairment and myocardial scar in early convalescence.
12 ease pathogenesis, response to therapies, or convalescence.
13 for the majority of observed phagocytosis at convalescence.
14 r to functional memory CD8(+) T cells during convalescence.
15 in reactivity to IgG1 and IgG3 antibodies at convalescence.
16 f individual memory B cells induced early in convalescence.
17 reased frequencies during acute COVID-19 and convalescence.
18 rocess regarding acute appendicitis, and its convalescence.
19 ness duration and gut microbiome profiles in convalescence.
20 PCR were performed at enrollment and during convalescence.
21 ed up to 8% during acute infection and early convalescence.
22 n (2.3%) or in early (26.6%) or late (58.6%) convalescence.
23 the late stages of acute disease or in early convalescence.
24 und to have severe unilateral uveitis during convalescence.
25 han those based on ecological competition by convalescence.
26 ral blood B cells during acute infection and convalescence.
27 n deposition and protected heart function in convalescence.
28 on methods are best utilized during presumed convalescence.
29 ed when IL-10 levels returned to baseline by convalescence.
30 t showed significant morbidity and prolonged convalescence.
31 roved intraoperative morbidity and decreased convalescence.
32 ldren (>=18 mo to 5 yr) during AVB and after convalescence.
33 eatment is effective but entails significant convalescence.
34 concentrations returning to baseline during convalescence.
35 ins associated with subclinical infection or convalescence.
36 ion decline in number and proportion by late convalescence.
37 F excretion, which returned to normal during convalescence.
38 the systemic angiogenic process during early convalescence.
39 rgence of neutralizing antibodies long after convalescence.
40 od loss, a shorter hospital stay, and faster convalescence.
41 des briefer, less intense, and more complete convalescence.
42 sion; bactericidal activity developed during convalescence.
43 d that IFA is useful for diagnosis of HGE in convalescence.
44 te disease (0.29 +/- 0.02 g/L) compared with convalescence (0.40 +/- 0.04 g/L), although not statisti
46 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinic
47 (43.5+/-14.1 vs. 45.7+/-25.3 hours, P =0.1; convalescence 23.5+/-5.3 vs. 20.2+/-4.1 days, P =0.5).
48 on i.e., at disease presentation compared to convalescence, 28 days post-infection defined by a follo
56 ions that include uveitis can develop during convalescence, although the incidence and pathogenesis o
57 ple aspects of CCHFV pathogenesis, including convalescence, an important aspect of CCHF disease that
59 -adjusted SR cutoffs of 0.6 mumol/L for late convalescence and 0.5 mumol/L for early convalescence, t
60 hospitalization, postoperative pain, time to convalescence and activity, while providing an optimal c
62 or post-EVD symptoms are common early during convalescence and decline over time along with severity.
64 e and impacts of SARS-CoV-2 infection during convalescence and for their role in immune host defense
65 such as fatigue or exertional dyspnea after convalescence and healthy control participants underwent
66 ical processes such as a temporary period of convalescence and pathogen-induced mortality have led to
68 nyan children with severe malaria and during convalescence and related these parameters to the adhesi
69 ere higher at hospital admission than during convalescence and that EPCR-rs867186 G allele was associ
71 mmediately after blood-stage infection or at convalescence, and for most subsets was directly associa
72 gher in severe than uncomplicated malaria in convalescence, and higher in children with blood group O
73 d to understand how the acute course of EVD, convalescence, and host immune and genetic factors may p
74 P lt 0.001) higher in the incubation, early convalescence, and late convalescence subgroups, respect
77 s during the transition from peak illness to convalescence, and these distinct inflammatory patterns
78 of acute pneumonia, to estimate mortality at convalescence, and to analyse mortality risk-factors.
82 s a result of prolonged hospitalizations and convalescence associated with antibiotic treatment failu
86 APP), incubation (elevated CRP only), early convalescence (both APP and CRP elevated), and late conv
87 Because of shortened hospitalization and convalescence, CAS challenges CEA as the preferred treat
89 L, and transfusion rates as well as improved convalescence compared with open-radical cystectomy.
90 h a briefer, less intense, and more complete convalescence compared with the open surgical approach.
91 obtained from three of these patients during convalescence contained antibodies that reacted with E.
95 ic surgeries offer added benefits of earlier convalescence, decreased blood loss, as well as decrease
97 ability to neutralize type 1 interferon into convalescence despite lower levels of binding immunoglob
98 g stability or decline of antibody titers in convalescence, efficacy of different vaccination regimen
100 understanding of CCHF, and investigation of convalescence following severe acute CCHF has been limit
102 ewer wound-related complications, and faster convalescence for patients who underwent laparoscopic ga
103 ring the acute phase of infection and during convalescence for WHcAg and WHxAg expression by immunohi
105 es ranging from acute ZIKV infection to late convalescence from individuals with evidence of prior DE
107 The Ab levels significantly declined during convalescence (> 90 days since onset of illness), compar
109 ude reduced postoperative pain and shortened convalescence; however, there are few data with respect
110 of plasma endothelial markers acutely and in convalescence in Malawian children with uncomplicated or
113 hat MPXV was cleared from most organs during convalescence, including healed skin lesions, but could
114 erentiate in a coordinated fashion well into convalescence into a state characteristic of long-lived,
115 he potential decrease in hospitalization and convalescence may also prove to be financially advantage
118 tracked their response through infection and convalescence.METHODSParticipants were injected intraven
119 Over the approximately six month period of convalescence monitored, we observed a slow and progress
121 of acute EVD with the following outcomes in convalescence: new ocular symptoms, uveitis, auditory sy
124 s, serum neutralizing antibody titers during convalescence, or duration of mechanical ventilation, in
130 e the serum neutralizing antibody responses, convalescence-phase serum samples from people previously
132 y, there was a strong, distinct signature of convalescence present at day 9 after infection that rema
135 o admission, hospital stay and postoperative convalescence (reflecting the consequences of delay in d
138 eral blood that changed during treatment and convalescence, returning in the majority of cases to the
140 he incubation, early convalescence, and late convalescence subgroups, respectively, with correspondin
141 undergo coronary angioplasty have a shorter convalescence than those who undergo coronary bypass sur
143 late convalescence and 0.5 mumol/L for early convalescence, the adjusted prevalence of SR deficiency
144 ecurrence, as well as postoperative pain and convalescence, the treatment of inguinal hernias underwe
146 n important role in decreasing postoperative convalescence through maintaining preoperative mydriasis
149 viduals shortly after infection and later in convalescence to determine the impact of maturation over
151 phages expressed pro-repair molecules during convalescence to promote the restoration of tissue integ
152 t were collected during acute EVD and during convalescence up to day 361 following illness onset.
153 admission and during hospital admission and convalescence (up to 30 days after onset of illness).
155 The titers both at presentation and after convalescence were not associated with the HRV genotype
156 f disease and 100% of the dogs tested during convalescence were seropositive for E. equi antigens.
160 his approach in regards to complications and convalescence without evidence of compromise to early an